Aspirin is the most commonly drug used to prevent thrombosis in atherosclerotic disease. The balance between platelet aggregation and its inhibition is crucial in clinical settings. Thromboxane A2 promotes aggregation and its inhibition by aspirin occurs via:
o Inhibition of arachidonic acid synthesis
o Inhibition of ADP synthesis
o Inhibition of Prostaglandin H2
o Inhibition of thrombin
o Inhibition of GP IIb/IIIa receptors
